Metal-Organic Framework as a New Type of Magnetothermally-Triggered On-Demand Release Carrier
© 2023 Wiley‐VCH GmbH..
The development of external stimuli-controlled payload systems has been sought after with increasing interest toward magnetothermally-triggered drug release (MTDR) carriers due to their non-invasive features. However, current MTDR carriers present several limitations, such as poor heating efficiency caused by the aggregation of iron oxide nanoparticles (IONPs) or the presence of antiferromagnetic phases which affect their efficiency. Herein, a novel MTDR carrier is developed using a controlled encapsulation method that fully fixes and confines IONPs of various sizes within the metal-organic frameworks (MOFs). This novel carrier preserves the MOF's morphology, porosity, and IONP segregation, while enhances heating efficiency through the oxidation of antiferromagnetic phases in IONPs during encapsulation. It also features a magnetothermally-responsive nanobrush that is stimulated by an alternating magnetic field to enable on-demand drug release. The novel carrier shows improved heating, which has potential applications as contrast agents and for combined chemo and magnetic hyperthermia therapy. It holds a great promise for magneto-thermally modulated drug dosing at tumor sites, making it an exciting avenue for cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Small (Weinheim an der Bergstrasse, Germany) - 20(2024), 12 vom: 21. März, Seite e2306940 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ge, Xueying [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/smll.202306940 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366186299 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366186299 | ||
| 003 | DE-627 | ||
| 005 | 20240325234531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/smll.202306940 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM366186299 | ||
| 035 | |a (NLM)38127968 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ge, Xueying |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metal-Organic Framework as a New Type of Magnetothermally-Triggered On-Demand Release Carrier |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley‐VCH GmbH. | ||
| 520 | |a The development of external stimuli-controlled payload systems has been sought after with increasing interest toward magnetothermally-triggered drug release (MTDR) carriers due to their non-invasive features. However, current MTDR carriers present several limitations, such as poor heating efficiency caused by the aggregation of iron oxide nanoparticles (IONPs) or the presence of antiferromagnetic phases which affect their efficiency. Herein, a novel MTDR carrier is developed using a controlled encapsulation method that fully fixes and confines IONPs of various sizes within the metal-organic frameworks (MOFs). This novel carrier preserves the MOF's morphology, porosity, and IONP segregation, while enhances heating efficiency through the oxidation of antiferromagnetic phases in IONPs during encapsulation. It also features a magnetothermally-responsive nanobrush that is stimulated by an alternating magnetic field to enable on-demand drug release. The novel carrier shows improved heating, which has potential applications as contrast agents and for combined chemo and magnetic hyperthermia therapy. It holds a great promise for magneto-thermally modulated drug dosing at tumor sites, making it an exciting avenue for cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hyperthermia treatment | |
| 650 | 4 | |a iron oxide nanoparticles | |
| 650 | 4 | |a magnetothermal | |
| 650 | 4 | |a metal–organic frameworks | |
| 650 | 4 | |a on‐demand drug release | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Metal-Organic Frameworks |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Mohapatra, Jeotikanta |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Enya |e verfasserin |4 aut | |
| 700 | 1 | |a He, Guihua |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Lingshan |e verfasserin |4 aut | |
| 700 | 1 | |a Lyu, Tengteng |e verfasserin |4 aut | |
| 700 | 1 | |a Madhogaria, Richa P |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Yuchuan |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Enizi, Abdullah M |e verfasserin |4 aut | |
| 700 | 1 | |a Nafady, Ayman |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, J Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Phan, Manh-Huong |e verfasserin |4 aut | |
| 700 | 1 | |a Taraballi, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Pettigrew, Roderic I |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Shengqian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Small (Weinheim an der Bergstrasse, Germany) |d 2005 |g 20(2024), 12 vom: 21. März, Seite e2306940 |w (DE-627)NLM167400452 |x 1613-6829 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:12 |g day:21 |g month:03 |g pages:e2306940 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/smll.202306940 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 12 |b 21 |c 03 |h e2306940 | ||